Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Hikma Pharmaceuticals Plc ADR (OP:HKMPY)

42.53 UNCHANGED

Streaming Delayed Price Updated: 12:29 PM EST, Jan 12, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	164
Open	42.53
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	42.53
Today's Range	42.53 - 42.53
52wk Range	39.93 - 59.26
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

March 20, 2025

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada

From Emergent BioSolutions

Via GlobeNewswire

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production ↗

September 06, 2024

Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Via Benzinga

Performance

YTD	+1.9%	+1.9%
1 Month	+4.4%	+4.4%
3 Month	-12.8%	-12.8%
6 Month	-20.0%	-20.0%
1 Year	-12.8%	-12.8%

More News

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices ↗

August 28, 2024

Via Benzinga

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

January 08, 2024

From Guardant Health, Inc.

Via Business Wire

Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape ↗

June 12, 2023

Via Benzinga

Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

December 26, 2022

From Junshi Biosciences

Via GlobeNewswire

Friday Markets News ↗

March 25, 2022

Via Talk Markets

Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)

August 27, 2021

From Bio-Thera Solutions, Ltd.

Via Business Wire

Summer Friday ↗

June 25, 2021

Via Talk Markets

Frequently Asked Questions

Is Hikma Pharmaceuticals Plc ADR publicly traded?

Yes, Hikma Pharmaceuticals Plc ADR is publicly traded.

What exchange does Hikma Pharmaceuticals Plc ADR trade on?

Hikma Pharmaceuticals Plc ADR trades on the OTC Traded

What is the ticker symbol for Hikma Pharmaceuticals Plc ADR?

The ticker symbol for Hikma Pharmaceuticals Plc ADR is HKMPY on the OTC Traded

What is the current price of Hikma Pharmaceuticals Plc ADR?

The current price of Hikma Pharmaceuticals Plc ADR is 42.53

When was Hikma Pharmaceuticals Plc ADR last traded?

The last trade of Hikma Pharmaceuticals Plc ADR was at 01/12/26 12:29 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.